相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Societal Cost of Schizophrenia: A Systematic Review
Huajie Jin et al.
PHARMACOECONOMICS (2017)
Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone
Bertalan Nemeth et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2017)
Economic burden of schizophrenia: the European situation. A scientific literature review
A Mancuso et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2017)
Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis
Kirsten Bjerkreim Strand et al.
HEALTH POLICY AND PLANNING (2016)
Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis
Liang Lin et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2016)
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
Sylvain Druais et al.
PHARMACOECONOMICS (2016)
The Business Case for Expanded Clozapine Utilization
Jessica L. Goeren et al.
PSYCHIATRIC SERVICES (2016)
An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013: a systematic literature review
Jason C. Simeone et al.
BMC PSYCHIATRY (2015)
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda
Solomon J. Lubinga et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2015)
Schizophrenia interventions in Vietnam: Primary results from a cost-effectiveness study
Nguyen Quynh Anh et al.
GLOBAL PUBLIC HEALTH (2015)
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison
Tatiana Dilla et al.
BMC PSYCHIATRY (2014)
SCHIZOPHRENIA Genesis of a complex disease
Jonathan Flint et al.
NATURE (2014)
Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
Taehwan Park et al.
VALUE IN HEALTH (2014)
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
Pierre Chue et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis
Fei-Li Zhao et al.
PHARMACOECONOMICS (2013)
Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score
Helen Dakin et al.
QUALITY OF LIFE RESEARCH (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
A Square Peg in a Round Hole? Challenges with DALY-based Burden of Disease Calculations in Surgery and a Call for Alternative Metrics
Richard Gosselin et al.
WORLD JOURNAL OF SURGERY (2013)
Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Eric D. A. Hermes et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence
Carla Dias Barbosa et al.
PATIENT PREFERENCE AND ADHERENCE (2012)
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden
Angelika Mehnert et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
Nicolas M. Furiak et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Health outcomes in economic evaluation: the QALY and utilities
Sarah J. Whitehead et al.
BRITISH MEDICAL BULLETIN (2010)
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
Maarten Treur et al.
BMC HEALTH SERVICES RESEARCH (2009)
Utility Assessment in Patients with Mental Disorders
Hans-Helmut König et al.
PHARMACOECONOMICS (2009)
Schizophrenia, just the facts 4. Clinical features and conceptualization
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2009)
Cost-Effectiveness of Long-Acting Risperidone Injection versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China
Li Yang et al.
VALUE IN HEALTH (2009)
Avaliação econômica do tratamento da esquizofrenia com antipsicóticos no Sistema Único de Saúde
Leandro Mendonça Lindner et al.
REVISTA DE SAUDE PUBLICA (2009)
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK
Andrew Davies et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation
Andrew Briggs et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2008)
Modelling approaches - The case of schizophrenia
Bart M. S. Hegg et al.
PHARMACOECONOMICS (2008)
A Pharmacoeconomic Analysis of Compliance Gains on Antipsychotic Medications
Joep Damen et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2008)
A taxonomy of model structures for economic evaluation of health technologies
Alan Brennan et al.
HEALTH ECONOMICS (2006)
Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach
Eric Q. Wu et al.
PSYCHOLOGICAL MEDICINE (2006)
Economic evaluation. Part 2: Frameworks for combining costs and benefits in health care
Emma McIntosh et al.
JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE (2006)
Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder
S. Potvin et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores (vol 71, pg 155, 2004)
LA Lenert et al.
SCHIZOPHRENIA RESEARCH (2005)
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)
RC Kessler et al.
BIOLOGICAL PSYCHIATRY (2005)
Pharmacoeconomic evaluation of schizophrenia in Taiwan: Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs
YK Yang et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2005)
A systematic review of the prevalence of schizophrenia
S Saha et al.
PLOS MEDICINE (2005)
Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up
P Milev et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany
G Laux et al.
PHARMACOECONOMICS (2005)
Modelling the treated course of schizophrenia: Development of a discrete event simulation model
BMS Heeg et al.
PHARMACOECONOMICS (2005)
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA
NC Edwards et al.
PHARMACOECONOMICS (2005)
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis
D De Graeve et al.
PHARMACOECONOMICS (2005)
Assessing cost-effectiveness of drug interventions for schizophrenia
A Magnus et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2005)
The heterogeneity of schizophrenia in disease states
PE Mohr et al.
SCHIZOPHRENIA RESEARCH (2004)
Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores
LA Lenert et al.
SCHIZOPHRENIA RESEARCH (2004)
A cost-effectiveness clinical decision analysis model for treatment of schizophrenia
CS Palmer et al.
ARCHIVES OF MEDICAL RESEARCH (2002)
分享论文
